Arvinas to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., May 02, 2024 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will...
Source: marketscreener.com